PRIME-ROSE

The EP PerMed Symposium on Ethical, Legal and Social Aspects (#ELSA) of #PersonalisedMedicine today addressed the main ethical challenges in personalised medicine research, with the aim of raising awareness and training researchers by addressing ELSA issues in personalised medicine from a macro approach (ethics of new technologies) to a specific approach (ethics, legal issues, privacy issues and artificial intelligence (#AI) in personalised medicine). Ethical principles in research are considered fundamental in the context of the European Union's Framework Programme for Research and Innovation Horizon Europe and are therefore mandatory for the research and innovation projects funded by EP PerMed. The event took place in a hybrid format with around 120 participants on site and online. A report on the symposium will be published in the coming weeks on the EP PerMed website. More: https://lnkd.in/e5cDb85J

Sharing is caring… ProTarget var godt repræsenteret på dette års ESMO-konference i Barcelona, bl.a. med en poster, der beskriver det unikke set-up i @PRIME-ROSE, hvor data fra alle de DRUP-lignende studier, som ProTarget, deles på tværs af Europa. 🎯 Datadeling skaber hurtigere et evidensbaseret grundlag for at finde præcis de patienter med kræft, der har gavn af målrettet behandling. Især for patienter med sjældne kræfttyper og varianter, som normalt ikke finder vej ind i lægemiddelforsøgene, er potentialet stort. 💡 Sammen med søsterstudierne i netværket holder vi månedlige møder, hvor vi ser på effekten af behandlingerne på tværs af vores studier, og i fællesskab vurderer om en given kohorte skal udvides med flere patienter, fordi behandlingen har effekt, eller lukke, fordi behandlingen ikke har effekt. Dette tætte samarbejde gør, at vi kan opnå resultater hurtigere end vi ville kunne hver især. 👀 Derfor var der stor interesse for PRIME-ROSE samarbejdet både blandt fagfolk og lægemiddelindustrien. Meldingerne fra dialogen i forbindelse med posterpræsentationen var, at PRIME-ROSE er et helt unikt netværk med et stort og værdifuldt potentiale. Så inspirerende at få ny viden og at knytte nye forbindelser og mærke også deres begejstring for ProTarget, de DRUP-lignende studier og PRIME-ROSE samarbejdet 👏 Følg os og vores arbejde for mere #precisionsmedicin ved at følge ProTarget Study eller #ProTargetDenmark Læs mere om PRIME-ROSE her: www.prime-rose.eu Tak til medforfatterne Tina Kringelbach, Gro Live Fagereng, Soemeya Haj Mohammad, Florentine Verbeek, Hans Timmer, Tanja Juslin, Loic Verlingue, Matthew Krebs, Jean-Yves Blay, Katriina Jalkanen, Kristoffer Rohrberg, Ulrik Niels Lassen, Åslaug Helland, Henk Verheul, Emile Voest, Hans Gelderblom og Kjetil Tasken #ESMO24 #ProTargetDenmark, #DRUP, #IMPRESSnorway, #FINPROVE Phase 1 Unit, Rigshospitalet, #Rigshospitalet

Evidence for the feasibility, early efficacy and safety of incorporating comprehensive #GenomicProfiling into clinical practice to provide #personalised treatments based on Drug Rediscovery Protocol-like Clinical Trials (DLCTs) was presented at #ESMO24. DLCTs explore the effects of #biomarker-driven treatments outside their approved indication(s) across a broad range of tumour types, thus enabling the study of #PrecisionOncology in large patient numbers, according to Vivek Subbiah, MD. 👇Read the full article on the #ESMODailyReporter https://ow.ly/tVNg50ToglA

Evidence for the feasibility, early efficacy and safety of incorporating comprehensive #GenomicProfiling into clinical practice to provide #personalised treatments based on Drug Rediscovery Protocol-like Clinical Trials (DLCTs) was presented at #ESMO24. DLCTs explore the effects of #biomarker-driven treatments outside their approved indication(s) across a broad range of tumour types, thus enabling the study of #PrecisionOncology in large patient numbers, according to Vivek Subbiah, MD. 👇Read the full article on the #ESMODailyReporter https://ow.ly/tVNg50ToglA

Check out all the activities from PRIME-ROSE and the DRUP-like clinical trials at #ESMO24. All posters are presented in Hall 6 on Sunday, 15th September at 12:00 – 13:00 o 197P - PRIME-ROSE: Merging clinical outcome data from DRUP-like clinical trials – Tina Kringelbach o 81P - FINPROVE: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs. Preliminary data after two years of enrollment – Katriina Jalkanen o 82P - Clinical and molecular characteristics of gynecologic cancer patients in FINPROVE – the national Phase II drug repurposing trial in Finland – Anniina Färkkilä o 89P - Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: a sub-project of the IMPRESS-Norway trial – Ingrid Dyvik o 130P - Ipilimumab plus Nivolumab (Ipi Nivo) in Patients with Tumors harboring High Tumor Mutational Burden or Load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP) – Soemeya Haj Mohammad o 228TiP - FINPROVE: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs – Mika Mustonen o 1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: joint collection and evaluation of real-world evidence – Sahar Barjesteh van Waalwijk van Doorn-Khosrovani Oral presentations at ESMO 2024: ESMO Track: The future of cancer via patient expertise in research & innovation projects, Sunday 15th September at 14:45-16:15, Zaragoza Auditorium – CC5 o Real world experience & patients' participation in multidisciplinary consortiums: the results from the PRIME-ROSE Community Advisory Board, PRO reporting – Bettina Ryll Mini oral session: Policy and preventive strategies, Monday 16th September at 14:45-16:15, Zaragoza Auditorium – CC5 o 1542MO - Mapping the scale of off-label use in oncology: an important step in harmonising access – Hans Timmer Multidisciplinary session, Monday 16th September at 16:30-17:45, Santander Auditorium - Hall 5 o Expanding proteome interrogation to identify early phase clinical trial biomarkers – Janne Lehtiö Kjetil Tasken Åslaug Helland Elisa Bjørgo Hege Russnes Kajsa Anna M Johansson ProTarget Study Ulrik Niels Lassen Kristoffer Rohrberg Tanja Juslin Edvard Abel Ebba Hallersjö Hult Edita Baltruskeviciene Anni Lepland Kristiina Ojamaa Hans Gelderblom Loic Verlingue Beatrice Mainoli Julio Oliveira Sarah Halford Claire L. Hyder Aida Sarmiento Castro, MSc, PhD Sarah Mellor https://lnkd.in/dGrsMvzU

Bringing the DRUG-Access Protocol to the EU to address uncertainties about real-world effectiveness & building strategies to maximize value #esmo2024 Emile Voest Haiko Bloemendal Hans Gelderblom Atse Huisman Simone Koole PRIME-ROSE #DAP

FINPROVE trial presented three posters at the #ESMO24 thank you so much for the presenting authors Katriina Jalkanen Anniina Färkkilä Mika Mustonen Read more from www.hus.fi/finprove #precisionmedicine #DrupLikeClinicalTrial

💥 The #PragmaTIL team participated in the first meeting of the Horizon Europe Cancer Mission “Diagnosis and Treatment-Refractory Cancer” Cluster (DCT)  at the Vall d'Hebron Institute of Oncology (VHIO) 💥 This cluster brings together 12 dedicated partners, working collaboratively to enhance treatment effectiveness and accelerate progress through knowledge sharing and the adoption of best practices. Special thanks to all the participating projects: CARE1, DE-ESCALATE Project IMPACT-AML, IMPORTANT EU Project IntReALL LEGATO Project  Sagittarius EU Project Liveration PRIME-ROSE SALVOVAR and STREXIT 2 Project for their invaluable insights and contributions! We look forward to continuing building these partnerships and advancing cancer treatment together 💪 Learn more ➡️ https://rb.gy/h6bpqz #EUCancerMission Gustave Roussy The Netherlands Cancer Institute CCIT-DK - National Center for Cancer Immune Therapy of Denmark Unicancer Seintinelles Fundación ”la Caixa” Innovandum BCN HEALTH ASPHALION Karolinska Institutet